Premium
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Author(s) -
Schmid Christoph,
Labopin Myriam,
Schaap Nicolaas,
Veelken Hendrik,
Schleuning Michael,
Stadler Michael,
Finke Juergen,
Hurst Erin,
Baron Frederic,
Ringden Olle,
Bug Gesine,
Blaise Didier,
Tischer Johanna,
Bloor Adrian,
Esteve Jordi,
Giebel Sebastian,
Savani Bipin,
Gorin NorbertClaude,
Ciceri Fabio,
Mohty Mohamad,
Nagler Ar
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15691
Subject(s) - medicine , transplantation , cytogenetics , myeloid leukaemia , stem cell , donor lymphocyte infusion , oncology , cohort , lymphocyte , chemotherapy , stage (stratigraphy) , leukemia , surgery , immunology , hematopoietic stem cell transplantation , chromosome , biochemistry , chemistry , genetics , biology , gene , paleontology
Summary Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry‐based matched‐pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair‐matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T‐cell depletion. Eighty‐nine pairs were identified (median follow‐up: 6.9 years). Within the entire cohort, no difference was observed. However, among patients with high‐risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls, P = 0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high‐risk AML.